Relevant conflicts of interest/financial disclosures: Irene Litvan was funded by 5R01AG024040-04. Charles Adler has been a consultant for Ipsen and Merck Serono, has been on the advisory boards of Biogen Idec, Eli Lilly, Medtronic, and Merz, and has received grants from the Arizona Biomedical Research Commission and the Michael J. Fox Foundation. Alexander I. Tröster has been a consultant for Medtronic, Inc., St. Jude, and Boston Scientific, has been on the advisory boards of Medtronic, Inc. and St. Jude, has received honoraria from Medtronic and Boehringer Ingelheim, and has received grants from the National Parkinson Foundation, GlaxoSmithKline, and Medtronic, Inc.
Article first published online: 9 JUN 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 10, pages 1814–1824, 15 August 2011
How to Cite
Litvan, I., Aarsland, D., Adler, C. H., Goldman, J. G., Kulisevsky, J., Mollenhauer, B., Rodriguez-Oroz, M. C., Tröster, A. I. and Weintraub, D. (2011), MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. Mov. Disord., 26: 1814–1824. doi: 10.1002/mds.23823
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 26 AUG 2011
- Article first published online: 9 JUN 2011
- Manuscript Accepted: 12 MAY 2011
- Manuscript Revised: 9 MAY 2011
- Manuscript Received: 28 FEB 2011
- mild cognitive impairment;
- Parkinson's disease;
- systematic review
There is controversy regarding the definition and characteristics of mild cognitive impairment in Parkinson's disease. The Movement Disorder Society commissioned a Task Force to critically evaluate the literature and determine the frequency and characteristics of Parkinson's disease–mild cognitive impairment and its association with dementia. A comprehensive PubMed literature review was conducted using systematic inclusion and exclusion criteria. A mean of 26.7% (range, 18.9%–38.2%) of nondemented patients with Parkinson's disease have mild cognitive impairment. The frequency of Parkinson's disease–mild cognitive impairment increases with age, disease duration, and disease severity. Impairments occur in a range of cognitive domains, but single domain impairment is more common than multiple domain impairment, and within single domain impairment, nonamnestic is more common than amnestic impairment. A high proportion of patients with Parkinson's disease–mild cognitive impairment progress to dementia in a relatively short period of time. The primary conclusions of the Task Force are that: (1) Parkinson's disease–mild cognitive impairment is common, (2) there is significant heterogeneity within Parkinson's disease–mild cognitive impairment in the number and types of cognitive domain impairments, (3) Parkinson's disease–mild cognitive impairment appears to place patients at risk of progressing to dementia, and (4) formal diagnostic criteria for Parkinson's disease–mild cognitive impairment are needed. © 2011 Movement Disorder Society